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Abstract: Histone deacetylases (HDAC) that regulate gene expression are being explored as cancer therapeutic targets. In this study, we focused on HDAC6 based on its ability to inhibit cancerous Hsp90 chaperone activities by disrupting Hsp90/p23 interactions. To identify novel HDAC6 inhibitors, we employed a dual-luciferase reporter system in cell culture and living mice by bioluminescence imaging (BLI). Based on existing knowledge, a library of hydrazone compounds was generated for screening by coupling cinnamic hydroxamates with aldehydes and ketones. Potency and selectivity were determined by in vitro HDAC profiling assays with further evaluation to inhibit Hsp90(α/β)/p23interactions by BLI. In this manner, we identified compound 1A12 as a dose-dependent inhibitor of Hsp90(α/β)/p23 interactions, UKE-1 myeloid cell proliferation, p21 waf1 upregulation and acetylated histone H3 levels. 1A12 was efficacious in tumor xenografts expressing Hsp90(α/β)/p23 reporters relative to carrier control treated mice as determined by BLI. Small animal for patients with advanced cutaneous T-cell lymphoma ( 6 -9 ) . HDAC inhibitors are also being evaluated in combination with other chemotherapy a n d t a r g e t e d agents, including DNA-damaging agents, inhibitors of methylthransferases, topoisomerases, kinases and t h e proteasome ( 1 0 , 1 1 ) .
The present cellular measurements of HDAC function, used in the study and We first harnessed the power of multimodality molecular imaging to evaluate the HDAC selectivity at cellular level. Using genetically-encoded split Renilla Luciferase (RL)
reporters, we have non-invasively monitored isoform-selective interactions between Hsp90(α/β) and the co-chaperone p23 in intact 293T human kidney cancer cells in cell culture and repetitively in living mice by optical bioluminescence imaging (BLI) ( 2 4 have recently used this system for successful evaluation and validation of a novel class of Hsp90 inhibitors in living mice (25) . In this report, we utilized our Hsp90(α/β)/p23 split reporter system to indirectly monitor the efficacy of different classes of HDACi in intact cells ( Figure 1A) . We have designed a n d synthesized a focused small-molecule HDACi library by direct coupling of a potent and HDAC-biased pharmacophore intermediate to a library of diverse aldehydes and ketones, to diversify compounds using a highly efficient chemical methodology developed previously by our groups (3). We then performed comparative dose-ranging biochemical assays to study target selectivity in a miniaturized format ( S u p p l e m e n t a l T a b l e 1) and cellular assays for disruption of Hsp90 function using our BLI system. These efforts led to discovery of a novel HDAC inhibitor 1A12. We demonstrate the efficacy of the lead compound 1A12 in disruption of Hsp90(α/β)/p23 by BLI and its inhibition of glucose metabolism in tumor xenografts of small animals by 18 F-FDG PET/CT imaging and up-regulation of HDAC biomarkers by ex-vivo analyses.
Materials and Methods
Reagents and Chemicals. Coelenterazine was purchased from Nanolight technology (Pinetop, AZ), dissolved in ethanol as 5mg/ml stock. All of the animal cell culture media, fetal bovine serum (FBS), the antibiotics streptomycin and penicillin (P/S), 4-12% gradient SDS-PAGE gels were purchased from Invitrogen (Carlsbad, CA supplemented with 10% FBS, 1% P/S solutions and 30 μg/ml puromycin hydrochloride.
NRL' refers to the 'N-terminal portion of RL (amino acid residues 1 -229) and 'CRL' refers to the C-terminal portion of RL amino acid residues 230 -311). M185V refers to the mutation in NRL that led to increase in light output (29) . We hypothesized that combination of Hsp90 and HDAC inhibitors would lead to additive effects in inhibition of Hsp90(α/β)/p23 interactions, which can be simultaneously monitored by our split reporter complementation system. To test our hypothesis, we utilized the prototypical HDAC6-specific inhibitor Tubacin ( 3 2 , 3 3 ) , which inhibits proliferation, alters microtubules dynamics, induces apoptosis and sensitizes cancer cells On the other hand, the control compound Niltubacin had no effect on Hsp90(α/β)/p23 interaction alone and did not enhance the efficacy of PU-H71 at the doses tested, relative to carrier control treated cells (Supplemental 1A). Similar results were seen with another Hsp90 inhibitor 17-DMAG in 293T cells (Supplemental Figures 1B and 2 ) and in MCF-7 cells that express the Hsp90(α/β)/p23 split RL reporters (data not shown).
To confirm that the decrease in BLI (Figures 1 and 2 ) correlates with the inhibition of HDAC6, the expression of p21 waf1 , acetylated histone H3 and acetylated α- 
Discovery of novel HDAC6 inhibitors through indirect monitoring of Hsp90(α/β)/p23
interactions in intact cells. In our previous study, we developed a convergent synthetic platform to establish a hydrazone library that enabled us to identify the selective HDAC inhibitors, provide structure-activity relationship (SAR), and discovered a pan-HDAC inhibitor pandacostat (3). Encouraged by this discovery, we further coupled para-and meta-cinnamic hydroxamates that are HDAC recognition biding warhead with more than 384 commercially available aldehydes (Supplemental Figure S3A) and ketones utilizing the hydrazone formation chemistry ( Figure 4A ) by coupling hydrazide directly to aldehydes and ketone in DMSO in a 96 well plate format, and generated a focused library of cinnamic hydroxamates with the structure diversity on the hydrazone end to explore the effect of cap space on the inhibition of HDAC activities ( Figure 4A ). All compounds were profiled with an in vitro fluorogenic HDAC assays (3) using purified proteins (HDACs 1-9) to confirm the activities and selectivity against HDAC 1-9 (Supplemental Figures S3B, S3C and Supplemental Table 1 
determined by western blotting. Figure 5D shows 2H9, 1A12 and 2C2 led to dosedependent increases in expression of p21 waf1 , acet-H3 and Hsp70 in 293T cells stably expressing the Hsp90α/p23 sensor, relative to carrier control treated cells. WT161 also led to up-regulation of p21 and acet-H3. PU-H71 led to increased expression of Hsp70 and p21 waf-1 as expected [35] , without affecting the levels of Acet-H3. Normalization to α-tubulin shows that 2C2, 1A12, 2H9 and WT161 led to increased expression of a c e t -H 3 a n d p21 waf-1 (Suppl. Figure S 4 ). Similar results were observed for that of 293T cells stably expressing Hsp90 /p23 sensor. In agreement with the RL imaging of Hsp90(α/β)/p23 interactions ( Figure 5C ), 1A12 was the most potent compound in upregulation of the expression of p21 waf1 and act-H3, followed by 2C2 and 2H9.
To further determine if the observed effects of 1A12 on inhibition of Hsp90(α/β)/p23 interactions and glucose metabolism was due to inhibition of HDAC activities, we synthesized a methyl ester
hydrazinecarbonyl)phenyl)propanoate, abbreviated as 1A12-ME). It is well known that hydroxamate is the binding head for HDAC (39, 40) , therefore we expected 1A12-ME with the methyl ester will not bind to HDAC6 or inhibits its activity due to lack of a double bond in the COHOH position.
To determine the specificity of 1A12-ME on inhibition of HDAC6, as well as HDAC1 and HDAC3, in vitro deacetylases assays were performed. Compared to SAHA, 1A12-ME had no effect on HDAC1, 3 and 6 activities except at the highest concentration tested (5 and 10 μM)
(Supplementary Figure S5A) . On the other hand, the IC 50 for 1A12 for inhibition of HDAC6 was 1.7 nM (Supplemental Table 1 ). 1A12-ME also did not lead to upregulation of HDAC biomarkers (acetylated histone H3, Acet-H3) in 293T cells stably expressing Hsp90(α/β)/p23 split RL reporters, compared to those treated with 1A12 ( Figure S5B ). To further confirm the specificity of 1A12 for inhibition of HDAC6 activity, 293T cells stably expressing Hsp90(α/β)/p23 split RL reporters were treated with different concentrations of 1A12 or 1A12-ME or the carrier control for 24 hours, prior to bioluminescence imaging (BLI) of Hsp90(α/β)/p23 interactions (RL imaging) and viable cell number (FL imaging) ( Figure S6A and data not shown). 1A12-ME had minimal effect on Hsp90(α/β)/p23 interactions (16% and 19% at 30 μM for Hsp90α/p23 and Hsp90β/p23 interactions, respectively), compared to that of 1A12 (46% and 44% at 30 μM for Hsp90α/p23 and Hsp90β/p23 interactions, respectively)(Supplemental Figure S6B) . Thus the activities of 1A12 reported on inhibition of Hsp90(α/β)/p23 interactions and subsequent glucose metabolism is specific for its ability to inhibit HDAC6. F-FDG uptake was calculated using the OSEM2D method upon normalization of injected dose ( 4 3 ) , and the % change at day 2 relative to day 0 was determined for each tumor site.
In carrier control treated mice, relative to time 0 hr, the mean increase in %ID/g of In the current work, we successfully incorporated multimodality molecular imaging into a discovery platform to identify novel cinnamic hydroxamates-based HDAC inhibitors.
We accomplished our goals of monitoring HDAC6 activities via BLI of Hsp90(α/β)/p23 interactions in intact cells. Upon validating the sensitivity and specificity our system with known HDACi, we focused our efforts on screening our custom synthesized compound library and discovered that the meta-cinnamic hydroxamate derivatives, such as the lead compound 1A12 have shown efficacy in disruption of Hsp90(α/p23 interactions. We have also non-invasively and repetitively monitored the inhibitory effects of 1A12 in 293T tumor xenografts in living mice on Hsp90α/p23 interactions b y B L I ( F i g u r e 6 ) and glucose metabolism by 18 Figure 7 ) and validated its mechanism as an HDAC inhibitor by ex-vivo analyses (Supplemental Figure 8) . Since the HDAC I selective inhibitors, such as MS275 did not provide the same effect on inhibition of Hsp90(α/β)/p23 interactions (Figures 2A and 3) , we proposed the effects on inhibition of glucose metabolism (Figure 7) we observed in tumor xenografts in mice was in part due to HDAC6 inhibition by 1A12. Figure   S6D ). In sum, our results indicated that 1A12 could be used as a second reporter to account for the change in viable cell number due to drug treatment. Using an inactive analogue of 1A12 (1A12-ME), we have further confirmed the biological effects of 1A12 were in part due to inhibition of HDAC6 (Supplemental Figures S5 and S6) .
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A unified dual split RL and FL reporter system accelerated drug discovery, mechanism validation and lead optimization in living subjects. Our split reporter assay ( Figure 1A ) allows us to specifically monitor the interactions between Hsp90(α/β) and p23 in intact cells, which is negatively regulated by HDAC6. Even though HDAC6-selective and pan-HDAC inhibitors can both lead to disruption of Hsp90(α/β)/p23 interactions, we can monitor its We utilized our Hsp90(α/β)/p23 split RL reporter system ( 2 5 ) for screening of novel HDAC inhibitors in cell culture and subsequently in living mice. Our strategy will allow rapid evaluation of different structural analogues generated by medicinal chemistry with better potency and bioavailability. The leads will then be tested in mice and this will significantly reduce the costs of scaling up the syntheses of compounds. Furthermore, the reporters can be introduced into specific cancer cell lines that over-express HDAC6 
